MedTrace Logo

Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.

NCT06097065 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2860

Last updated 2023-10-24

No results posted yet for this study

Summary

Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.

Conditions

Interventions

DIAGNOSTIC_TEST

Oral Glucose Tolerance Test

Grouping based on detected oral glucose tolerance test results without any other intervention.

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Hongwei Zhou, Professor · Zhujiang Hospital

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-20
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097065 on ClinicalTrials.gov